Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Income from Continuing Operations (2016 - 2025)

United Therapeutics (UTHR) has disclosed Income from Continuing Operations for 17 consecutive years, with 364300000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations rose 20.91% to 364300000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1334700000.0 through Dec 2025, up 11.68% year-over-year, with the annual reading at 1334700000.0 for FY2025, 11.68% up from the prior year.
  • Income from Continuing Operations hit 364300000.0 in Q4 2025 for United Therapeutics, up from 338700000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 364300000.0 in Q4 2025 to a low of 28300000.0 in Q1 2021.
  • Historically, Income from Continuing Operations has averaged 235885000.0 across 5 years, with a median of 250050000.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 79.45% in 2021 and later surged 747.7% in 2022.
  • Year by year, Income from Continuing Operations stood at 112200000.0 in 2021, then rose by 17.74% to 132100000.0 in 2022, then surged by 64.35% to 217100000.0 in 2023, then surged by 38.78% to 301300000.0 in 2024, then increased by 20.91% to 364300000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for UTHR at 364300000.0 in Q4 2025, 338700000.0 in Q3 2025, and 309500000.0 in Q2 2025.